In the United Kingdom, cell culture company CellulaREvolution has wound down operations and is seeking buyers for its assets, having run out of funding.
Spun out from Newcastle University in 2018, the company provided bottleneck-busting enzyme technologies for cultivated meat, regenerative medicine and vaccine sectors.
“We couldn’t deliver commercial milestones fast enough to secure Series A investment. The bar is higher than anyone (in 2021) could have foreseen,” CEO Chris Green told Green Queen.
Its first product was AggreGuard, an enzyme blend that stops cells from clumping—boosting yields and reducing waste.
In late 2023, CellRev partnered with BSF Enterprise for the joint venture Cultivated Meat Technologies Limited, which would have mass-produced cultivated meat in a cost-effective manner. However, BSF called off the joint venture last year.